According to Zhitong Finance App, Hengrui Pharmaceutical (01276) announced the results for the first three quarters of 2026, with revenue of about 24.409 billion yuan, up 5.26% year on year; net profit attributable to shareholders of listed companies was about 6.923 billion yuan, up 20.38% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 6.243 billion yuan, up 11.70% year on year; basic earnings per share were 1.05 yuan. The company continues to increase its innovation efforts and maintain a high level of R&D investment. In the first three quarters of 2026, the company invested 7.146 billion yuan in R&D, of which 5.423 billion yuan was spent on costed R&D.
In the first three quarters of 2026, the company's innovative drug sales revenue was 13.871 billion yuan, an increase of 17.05% over the previous year, and its share of drug sales revenue increased to 64.59%. Of the sales revenue of innovative drugs, the revenue of innovative anti-tumor products was 9.865 billion yuan, an increase of 3.13% over the previous year, accounting for 71.12% of the total sales revenue of innovative drugs. Revenue from innovative non-oncology products was 4.06 billion yuan, an increase of 75.36% over the previous year, accounting for 28.88% of the overall sales revenue of innovative drugs.
In the first three quarters of 2026, the company's innovative drug licensing business confirmed revenue of 2,781 billion yuan, an increase of 31.12% over the previous year, mainly revenue confirmed by GSK and BMS in accordance with the completion progress of performance obligations and milestone payments for individual authorized products; the company received a total of 4.343 billion yuan in down payments and milestone cash for external licensing cooperation, mainly US$600 million down payment from BMS.